SOCIETY OF HEMATOLOGIC ONCOLOGY
SOHO 2026September 9-12, 2026 Houston
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| ABCL-026 | A Manifold-Based Topological Approach for Identifying Stage-Divergent Apoptotic Signatures in DLBCL | Alamin Mustafa |  Received |
 |
|||
| AML-037 | Topological Reconstruction of DNA Repair Signatures and Survival Divergence in Acute Myeloid Leukemia | Alamin Mustafa | Received |
|
|||
| ABCL-086 | Trial in Progress (IGNITE): A Phase 3, Multiregional, Open-Label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide (RTX-TMZ) in Relapsed/Refractory (R/R) Primary Central Nervous System Lymphoma (PCNSL) | Kelly McGinty | Received |
|
|||
| AML-087 | Nationwide Trends in Acute Myeloid Leukemia Mortality Arising From Philadelphia Chromosome-Negative Myeloproliferative Neoplasms in the United States, 1999–2023 | Valerin Arno Encarnacion | Received |
|
|||
| MDS-113 | Updated overall survival and long-term transfusion independence from the phase 3 COMMANDS trial in erythropoiesis-stimulating agent−naive patients with lower-risk myelodysplastic syndromes | Ally Bousema | Received |
|
|||
| MM-116 | AI-Assisted Simplification of Clinic Notes for Patients With Plasma Cell Dyscrasias and Myeloid Neoplasms to Improve Patient Understanding and Satisfaction: A Prospective Pilot Study | Karun Neupane | Received |
|
|||
| CLL-119 | Clinical Outcomes and Predictors of Early Inpatient CAR-T Administration Within 48 Hours: A Nationwide Analysis | Fiqe Khan | Received |
|
|||
| MPN-161 | Benefit of Rusfertide Maintained in Patients With Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study | Mary Dawod | Received |
|
|||
| ABCL-174 | Disseminated Extranodal Diffuse Large B-Cell Lymphoma With Genitourinary and Extensive Osseous Involvement Mimicking Metastatic Solid Malignancy | nahla khalil | Received |
|
|||
| CT-227 | Measurable Residual Disease by Circulating Tumor DNA in Patients With Third-Line or Later Relapsed or Refractory Follicular Lymphoma Treated With Lisocabtagene Maraleucel in TRANSCEND FL | Alex Verdeur | Received |
|
|||
| CT-228 | Outcomes of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: First Real-World Data From the CIBMTR | Alex Verdeur | Received |
|
|||
| MM-251 | Distinct Inpatient and Post-Discharge Risk States Defined by AKI and Acute Dialysis in Multiple Myeloma Hospitalizations | Woo Joo Lee | Received |
|
|||
| AML-252 | Concentration of Hemorrhagic Burden and Interhospital Transfer Vulnerability in Acute Promyelocytic Leukemia: A Nationwide Analysis, 2016–2022 | Woo Joo Lee | Received |
|
|||
| MPN-269 | Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis From IMbark Versus Real-World Data and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow-Up | Mary Ellyn Zola | Received |
|
|||
| ALL-280 | Topological Simplification and Loss of Regulatory Complexity in the DNA Repair Pathway of Acute Lymphoblastic Leukemia | Alamin Mustafa | Received |
|
|||
| IBCL-290 | Light Chain Amyloidosis in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Treatment Strategies and Outcomes of 74 Cases | Nicolò Danesin | Received |
|
|||
| MPN-298 | Correlation Among IL-8, TNF-a, and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus Kinase Inhibitor (JAKi) in the IMbark Trial | Mary Ellyn Zola | Received |
|
|||
| ABCL-346 | Real-World Comparative Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel and Bispecific Antibodies in Third-Line or Later Large B-Cell Lymphoma | Alex Verdeur | Received |
|
|||
| AML-384 | Venetoclax?in Combination With?a Hypomethylating Agent for Patients With?Newly Diagnosed Acute Myeloid Leukemia Who Are?Medically?Unfit for Intensive Induction Therapy: A Real-World Community Experience | Chiara Perni | Received |
|
|||
| MPN-425 | Baseline Predictors of Survival and Spleen Response in Ruxolitinib-Treated Myelofibrosis: Development of the Ruxolitinib Prognostic Scoring System in a Real-World Cohort | Alessandro Laganà | Received |
|
|||
| ABCL-438 | Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LCBL): Updated efficacy and safety from the Phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups | Isobel Neill | Received |
|
|||
| CLL-450 | Pirtobrutinib versus covalent BTK inhibitors in treatment-naïve CLL: a systematic review and network meta-analysis | Junaid Anwar | Received |
|
|||
| MM-467 | Identification of RNASEL and ROCK1 as Geometric Bottlenecks in Multiple Myeloma via Discrete Ricci Curvature Analysis | Alamin Mustafa | Received |
|
|||
| ABCL-483 | Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab Plus GemOx (R-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the 3-Year Follow-Up of STARGLO | Isobel Neill | Received |
|
|||
| IBCL-510 | Clinical Characteristics and Survival Outcomes in Waldenström Macroglobulinemia: An Updated Analysis of 10574 Patients From the SEER Database (1975–2020) | Alamin Mustafa | Received |
|
|||
| ABCL-568 | Subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin shows a sustained progression-free survival (PFS) benefit compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) large B-cell lymphoma after long-term follow-up | Isobel Neill | Received |
|
|||
| MM-578 | Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results From the CC-220-MM-001 Trial | Jenny Mark | Received |
|
|||
| AML-623 | Long-term follow-up of pediatric/young adult patients with relapsed/refractory KMT2Ar acute leukemia treated with revumenib in AUGMENT-101 | Anna Sitarski | Received |
|
|||
| AML-632 | Revumenib Therapy Post-Hematopoietic Stem Cell Transplant for Patients With Relapsed/Refractory KMT2Ar, NPM1m, and NUP98r Acute Myeloid Leukemia: Post Hoc Analysis of Outcomes From AUGMENT-101 | Anna Sitarski | Received |
|
|||
| AML-712 | Revumenib plus intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated phase 1 results from SNDX-5613-0708 | Anna Sitarski | Received |
|
|||
| AML-723 | Clinical Activity of Revumenib in Patients With Relapsed/Refractory NUP98-Rearranged Acute Leukemias | Anna Sitarski | Received |
|
|||
| ABCL-736 | Outpatient Treatment With Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety Results From a Phase 2 Study | Isobel Neill | Received |
|
|||
| AML-773 | Efficacy of Revumenib in Acute Myeloid Leukemia Harboring NPM1-Mutated Co-Mutations: Post Hoc Analysis of AUGMENT-101 | Anna Sitarski | Received |
|
|||
| MM-803 | Correlation Between Mobilization Regimen and CD34? Stem Cell Yield in Multiple Myeloma (MM) Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT): A Single-Center Retrospective Analysis | Solomiia Hlukhovska | Received |
|
|||
| MPN-985 | Effect of rusfertide on cytoreductive therapy use in patients with phlebotomy dependent polycythemia vera: post hoc analysis from the randomized controlled phase 3 VERIFY study | Mary Dawod | Received |
|
|||
| AML-1008 | Clinicopathological features, co-mutational patterns and outcomes in NPM1-mutated adult acute myeloid leukemia patients treated at Singapore General Hospital | Than Hein | Received |
|
|||
| HL-1010 | Health-Related Quality of Life of Patients With Advanced-Stage Classic Hodgkin Lymphoma Treated With BrECADD and eBEACOPP: Results From the HD21 Study | Fjoralba Kristo | Received |
|
|||
| HL-1012 | Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated with BrECADD and eBEACOPP: New Data from the HD21 Trial | Fjoralba Kristo | Received |
|
|||
| MM-1098 | Racial and Ethnic Disparities in Radiation Therapy Utilization Among Patients With Multiple Myeloma and Bone Metastasis: A Real-World Analysis Using TriNetX | Juhi Ardeshna-Chovatiya | Received |
|
|||
| AML-1204 | Real-World Incidence of Severe Ventricular Arrhythmias in Patients with Acute Myeloid Leukemia Treated with Quizartinib: Interim Results From a Postmarketing Study | Oluwatosin Fofah | Received |
|
|||
| TCL-1326 | Treatment Outcomes and Prognostic Factors in Elderly Patients with Newly Diagnosed Peripheral T-Cell Lymphoma | Omar Elghawy | Received |
|
|||
| AML-1410 | Characteristics and Clinical Outcomes of Patients With Myeloid Malignancies and Cohesin Mutations | Maria Khouri | Received |
|
|||
| IBCL-1506 | Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect of Epcoritamab (E) With Lenalidomide and Rituximab (R2) in Relapsed/Refractory Follicular Lymphoma (R/R FL) | Sabrina Singleton | Received |
|
|||
| MM-1644 | Impact of Diabetes Mellitus on Outcomes in Multiple Myeloma Patients Receiving Bispecific Antibodies: A Real-World Analysis | Juhi Ardeshna-Chovatiya | Received |
|
|||
| ABCL-1652 | Impact of Diabetes Mellitus on Outcomes and Toxicity in Patients With Diffuse Large B-Cell Lymphoma Treated With Bispecific Antibodies: A Real-World Propensity Score-Matched Analysis | Juhi Ardeshna-Chovatiya | Received |
|
|||
| MM-1659 | Prophylactic Tocilizumab During Bispecific Antibody Step-Up Dosing in Relapsed/Refractory Multiple Myeloma: CRS Mitigation, Low-Dose Strategies, and Outpatient Feasibility | Valerin Arno Encarnacion | Received |
|
|||
SOHO 2026
September 9-12, 2026 Houston
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 09/09/2026 TO 09/09/2026
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
Poster submission deadline 28/08/2026
|
|
